Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 3/20 | 0.62 |
| ▸ | CACNA1D | Q01668 | 3/20 | 0.62 |
| ▸ | CACNA1S | Q13698 | 3/20 | 0.62 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718828 | 1.00 | CYP1A2 (1.00) | CYP1A2ADORA3MAPTCACNA1CCYP3A4 | |
| SCHEMBL2845539 | 1.00 | CYP1A2 (1.00) | CYP1A2ADORA3MAPTCACNA1CCYP3A4 | |
| SCHEMBL30897545 | 1.00 | CYP1A2 (1.00) | CYP1A2ADORA3MAPTCACNA1CCYP3A4 | |
| SCHEMBL133106 | 1.00 | CYP1A2 (1.00) | CYP1A2ADORA3MAPTCACNA1CCYP3A4 | |
| SCHEMBL14612812 | 0.90 | CYP1A2 (0.82) | CYP1A2ADORA3MAPTCACNA1CCYP3A4 | |
| SCHEMBL7265346 | 0.89 | CYP1A2 (0.80) | CYP1A2ADORA3MAPTCACNA1CCYP3A4 | |
| SCHEMBL11369967 | 0.89 | CYP1A2 (0.79) | CYP1A2ADORA3MAPTCACNA1CCYP3A4 | |
| SCHEMBL11004406 | 0.89 | CYP1A2 (0.79) | CYP1A2ADORA3MAPTCACNA1CCYP3A4 | |
| SCHEMBL7272013 | 0.88 | MAPT (0.79) | CYP1A2ADORA3MAPTCACNA1CCYP3A4 | |
| SCHEMBL28830138 | 0.87 | MAPT (0.78) | CYP1A2ADORA3MAPTCACNA1CCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 589 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116355836-B | Bile duct trunk cell expansion or passage system and application thereof | 上海市东方医院（同济大学附属东方医院） | 2026-05-19 | — | — | CN | claimed |
| US-12570957-B2 | Isolated naive pluripotent stem cells and methods of generating same | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2026-03-10 | — | — | US | claimed |
| US-20250222028-A1 | ENGINEERED IMMUNE CELL PLATFORM | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-10 | — | — | US | claimed |
| US-20250152531-A1 | INHIBITORS OF AUTOPHAGY AND DCAR-1 AS NOVEL ANTHELMINTIC AGENTS | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES | 2025-05-15 | — | — | US | claimed |
| US-12233036-B2 | Inhibitors of autophagy and DCAR-1 as novel anthelmintic agents | FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (US) | 2025-02-25 | — | — | US | claimed |
| EP-4499135-A1 | ENGINEERED IMMUNE CELL PLATFORM | Cancer Research Technology Limited (GB) | 2025-02-05 | — | — | EP | claimed |
| CN-119314440-A | High PPI HDM flicker adjustment process | 无锡夏普显示科技有限公司 | 2025-01-14 | — | — | CN | claimed |
| CN-119274499-A | Automatic debugging method, system, device and terminal for automatic backlight curve | 四川酷比通信设备有限公司 | 2025-01-07 | — | — | CN | claimed |
| CN-119013039-A | Engineered immune cell platform | 癌症研究技术有限公司 | 2024-11-22 | — | — | CN | claimed |
| US-20240318144-A1 | MEDIA FOR CULTURING NAIVE HUMAN PLURIPOTENT STEM CELLS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-09-26 | — | — | US | claimed |
| CN-116844461-A | Color difference adjusting method and system for spliced screen | 深圳新视光电科技有限公司 | 2023-10-03 | — | — | CN | claimed |
| CN-116774472-A | Method and system for evaluating graphic effect of liquid crystal display | 深圳市巨潮科技股份有限公司 | 2023-09-19 | — | — | CN | claimed |
| CN-116777876-A | Image quality evaluation method and system for medical image display equipment | 深圳市巨潮科技股份有限公司 | 2023-09-19 | — | — | CN | claimed |
| US-11730769-B2 | Compositions and methods for Williams Syndrome (WS) therapy | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-08-22 | — | — | US | claimed |
| CN-116355836-A | Bile duct trunk cell expansion or passage system and application thereof | 上海市东方医院（同济大学附属东方医院） | 2023-06-30 | — | — | CN | claimed |
| US-11572540-B2 | Method for inducing oligodendrocyte precursor cells from OCT4-induced human somatic cells through direct reprogramming | Stemlab Inc. (KR) | 2023-02-07 | — | — | US | claimed |
| WO-2022254442-A1 | MEANS AND METHODS FOR IMPROVING ANTI-TUMORAL EFFICACY OF TRANSMEMBRANE CHANNEL PROTEIN BLOCKERS | ARDAN PHARMA S.A.S. (AR) | 2022-12-08 | — | — | WO | claimed |
| CN-113151157-B | Passage method and application of endoderm stem/progenitor cells obtained by reprogramming epithelial cells derived from digestive tract | 中国人民解放军军事医学科学院野战输血研究所 | 2022-06-28 | — | — | CN | claimed |
| US-11332716-B2 | Methods and compositions for producing pancreatic beta cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-17 | — | — | US | claimed |
| WO-2022065859-A1 | METHOD FOR DIRECT REPROGRAMMING FROM SOMATIC CELLS INTO PANCREATIC BETA CELLS BY USING MICRORNA, AND DIFFERENTIATION COMPOSITION | 성균관대학교산학협력단 | 2022-03-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730769-B2 | Compositions and methods for Williams Syndrome (WS) therapy | MAG, PMP22, WDR77 | CYP1A2 4855/4885ADORA3 4569/4885MAPT 1134/4885 |
| US-12570957-B2 | Isolated naive pluripotent stem cells and methods of generating same | GSK3B, EZH2, GSK3A | CYP1A2 4392/4885ADORA3 3689/4885MAPT 1643/4885 |
| US-11332716-B2 | Methods and compositions for producing pancreatic beta cells | IAPP, ALPG, AMY2A | CYP1A2 4820/4885ADORA3 3401/4885MAPT 4517/4885 |
| US-20250222028-A1 | ENGINEERED IMMUNE CELL PLATFORM | CACNA1C, CACNA1S, CACNB1 | CYP1A2 4421/4885ADORA3 1038/4885MAPT 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.